AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05169918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensorial Discrimination Training
Description: Training group will be participate in core stabilization exercises (as describe in Control Group). Additionally, Sensorial Discrimination Training (SDT) will be applied on the low back of the patients for 20 minutes before the 20 minutes of core stabilization exercises. SDT is defined as the ability to correctly interpret the characteristics of the stimulus made to a part of the body by the patient. It aims to reverse the cortical reorganization observed in patients with chronic pain. It consists of tactile localization and graphesthesia training, which includes determining the localization and type of stimulus and recognizing the letter/number that drawn in a body part, by the patient. The training consists of five stages progressively, each stage lasting two weeks. As the participants complete the sensory tests at each stage with 90% accuracy, the next stage will be passed. If this accuracy rate is not achieved within two weeks, the stage can be extended for one week.
Study NCT05440513 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal Pelvic Denervation (bilateral)
Description: Using the natural orifice of the urethra, the ureters are accessed (bilaterally and in sequence), to allow for an ablation device to be placed into the renal pelvis where RF energy is delivered to ablate renal nerves.
Study NCT06491771 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TargetCool
Description: The patients were treated with TargetCool via boosting mode combined with tranexamic acid and normal saline on each side of cheek for 4 times every 1 week
Study NCT06491771 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TargetCool
Description: The patients were treated with TargetCool via boosting mode combined with tranexamic acid and normal saline on each side of cheek for 4 times every 1 week
Study NCT06244511 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early Bipedal Exercise
Description: Proprioceptive, resistive, nuromuscular exercises and stretching; Exercise interventions involving the active use of both extremities will be implemented for the first four weeks.
Study NCT06244511 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Late Bipedal Exercise
Description: Proprioceptive, resistive, nuromuscular exercises and stretching; Exercise interventions involving the active use of both extremities will be implemented for the last four weeks.
Study NCT06457425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flonoltinib 50mg
Description: Flonoltinib 50mg
Study NCT06457425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flonoltinib 100mg
Description: Flonoltinib 100mg
Study NCT06457425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: For patients with platelet counts between 100×10\^9/L and 200×10\^9/L, the recommended starting dose is 15 mg twice daily (bid). For patients with platelet counts >200×10\^9/L, the recommended starting dose is 20 mg bid. For patients with platelet counts between 50×10\^9/L and \<100×10\^9/L, the recommended maximum starting dose is 5 mg bid.
Study NCT06108401 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Goat milk-based infant formula
Description: Goat milk-based infant formula exclusively for 4 weeks at a volume depending on the infant.
Study NCT06108401 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cow milk-based infant formula
Description: Regular cow milk-based infant formula that is similar in color, smell, and taste to the formula received by the experimental group.
Study NCT05673629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone Injection in combination with AC
Description: The treatment group will be treated with Utidelone Injection at 30 mg/m2/d administered intravenously once daily on days 1-5 of each cycle, and Doxorubicin Injection at 50mg/m2 and Cyclophosphamide Injection at 500 mg/m2, administered intravenously respectively once daily on day 1 of each cycle. One treatment cycle has 21 days, and there are 6 cycles in total.~After the neoadjuvant therapy, all patients suitable for surgery will have the operation, and they will be evaluated pre-operatively for clinical remission according to RECIST 1.1. For patients unsuitable for surgery, they will receive other treatments according to the clinical practice at each site.~Safety evaluation will be performed 28 days after the last dose, and patients will be followed up for at least 3 years for disease recurrence.
Study NCT05673629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel Injection in combination with AC
Description: The control group will be treated with Docetaxel Injection at 75 mg/m2, Doxorubicin Injection at 50 mg/m2, and Cyclophosphamide Injection at 500mg/m2, administered intravenously once on day 1 of each cycle. One cycle has 21 days, and there are 6 cycles in total.~After the neoadjuvant therapy, all patients suitable for surgery will have the operation, and they will be evaluated pre-operatively for clinical remission according to RECIST 1.1. For patients unsuitable for surgery, they will receive other treatments according to the clinical practice at each site.~Safety evaluation will be performed 28 days after the last dose, and patients will be followed up for at least 3 years for disease recurrence.
Study NCT06514092 — intervention group
Intervention type: OTHER
Intervention: anti-TNF therapy and seton drainage
Description: Crohn's disease patients who have undergone treatment with anti-TNF therapy and seton drainage.
Study NCT05544539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozone-Based Agent
Description: In the study group Ozone oil was placed inside the socket of the extracted tooth following suturing of the flap
Study NCT05544539 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the control group Ozone oil syringe was placed inside the socket of the extracted tooth without applying the oil
Study NCT05952908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proficiency-Based Progression simulation training
Description: The simulation-based training curriculum is delivered - with proficiency requirements - with the aim of further enhancing trainees' implant skills, as an optional supplement to their academic/institutional training.
Study NCT06004414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App-based Cognitive Behavioral Therapy (CBT)
Description: SilverCloud is organized into eight core modules that follow evidence-based principles of CBT, along with six additional modules that can be prescribed by the clinician to address a participant's specific needs.
Study NCT06004414 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: Psychotherapy with a licensed clinician in the school-based health center.
Study NCT04184323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EX-527 (Selisistat)
Description: EX-527 is a specific inhibitor of the histone deacetylase Sirtuin-1 (SirT1). It is being given to reverse the effects of endometriosis, namely progesterone resistance, that is thought to interfere with the establishment of pregnancy in women with endometriosis
Study NCT04184323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: We will use the same vehicle for producing the active drug such as maltose without any hormones or active components
Study NCT05343338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sivelestat sodium
Description: After dissolving sivelestat sodium with 0.9% sodium chloride injection, dilute the 1-day dose (4.8 mg/kg) with 50 mL of 0.9% sodium chloride injection and continue intravenously at a rate of 0.2 mg/kg/h for administration. The start time of administration was after induction of anesthesia, and at the same time, the extracorporeal circulation circuit is prefilled with 100 mg. The end time is 48 hours after admission to the ICU.
Study NCT04836936 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Auriculotherapy cryopuncture device without nitrogen gas
Description: Auriculotherapy cryopuncture device without nitrogen gas will be administered. Application of this placebo device will be performed in the same manner as the treatment, but without the expulsion of nitrogen gas.
Study NCT04836936 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auriculotherapy cryopuncture device with nitrogen gas
Description: Auriculotherapy cryopuncture device with nitrogen gas will be administered. The tip of the cryopuncture will be sanitized and placed on each treatment point of the ear, releasing a spurt of nitrogen gas for 2 seconds on each point (6 points total).
Study NCT06384950 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ChatGPT
Description: Patients receive additional education using a GPT-3.5-based educational robot on top of the traditional education.
Study NCT06384950 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: patient education with traditional methods.
Description: Patients receive standard traditional education procedures.
Study NCT06579274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parecoxib
Description: Parecoxib (Dynastat) 40 mg solution for injection is for intravenous administration. Parecoxib may be given as an intravenous injection for 30 minutes directly into a vein or through an intravenous infusion set.
Study NCT06579274 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous injection can be administered quickly and directly into a vein or through an intravenous infusion set.
Study NCT05295966 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive therapy
Description: Cognitive therapy
Study NCT05295966 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Description: Cognitive therapy
Study NCT05295966 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiocognitive Integration
Description: Physiocognitive Integration
Study NCT05952908 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional simulation training
Description: The simulation-based training curriculum is delivered - without proficiency requirements - with the aim of further enhancing trainees' implant skills, as an optional supplement to their academic/institutional training.
Study NCT06384248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTC004
Description: LTC004,45μg/kg,IV,Day 1,Q3W;
Study NCT05373355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLL018 tablets
Description: Oral tablets administered at different doses BID daily for 12 weeks.
Study NCT05373355 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TLL018 tablets
Description: Oral tablets administered at different doses BID daily for 12 weeks.
Study NCT05580666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Oral Tablet
Description: Antimicrobial therapy
Study NCT05580666 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Inert ingredients
Study NCT05867654 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Amoxicillin-clavulanate 875mg/125mg q12hrs
Description: Oral antibiotic used based on indication
Study NCT05867654 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: oral clindamycin 300mg q6hrs
Description: Oral antibiotic used based on indication
Study NCT05867654 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Levofloxacin 750mg QID
Description: Oral antibiotic used based on indication
Study NCT05120115 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight belt
Description: Wearing belt around waist with various weights attached.
Study NCT05001360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XBI-302 + Nivolumab
Description: After gut preparation, a single dose of FMT will be performed via oral administration. Subsequently, nine combined treatment cycles that composed of anti-PD-1 infusions (Nivolumab at 240 mg, q2w) and additional FMT capsules, and 3 single treatment cycles of anti-PD-1 infusions will be administered.
Study NCT06187740 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: thoracic radiotherapy
Description: Thoracic radiotherapy should begin within 42 days after the end of the last chemotherapy at an initial dose of 30 Gy in 10 fractions (3 patients).~Dose escalation will start after acceptable safety was observed, first at: 35 Gy/10 Fx(3 patients), then to the next dose group: 40 Gy/10 Fx(22 patients). Radiotherapy was administered between two immunotherapy doses (3 weeks interval) to avoid thoracic radiotherapy on the same day with immunotherapy.
Study NCT04782557 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EUS-guided portal vein and hepatic vein aspiration
Description: EUS-guided portal vein and hepatic vein aspiration
Study NCT05895110 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Novel Coronavirus vaccine (CHO Cells)
Description: The experimental vaccine dose used in this study is 25μg/0.5mL. All subjects recruited should have received two doses of novel Coronavirus inactivated vaccine on the market for 6-9 months, and all eligible subjects will receive one dose of recombinant Novel Coronavirus vaccine (CHO cells).
Study NCT06032377 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy for sleep, anxiety, and depression
Description: This intervention addresses insomnia, anxiety and depression via modules covering all the core CBTi components: psychoeducation about insomnia, relaxation, cognitive restructuring, stimulus control, sleep restriction and stress management; as well as psychoeducation about anxiety and low mood, behavioral activation strategies, and strategies to better manage ruminations. The modules are adapted to older adults and include short texts, pictures, quizzes with feedback, interactive exercises, logbooks, audio and video recordings.
Study NCT06032377 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: education about healthy nutrition habits and communication in older age
Description: This intervention addresses healthy nutrition habits as well as communication and aging. The modules are adapted to older adults and include short texts, pictures, quizzes with feedback, interactive exercises, logbooks, audio and video recordings
Study NCT06133751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: black chokeberry (Aronia melanocarpa)
Description: Black chokeberry capsules standardized for anthocyanin compounds
Study NCT06133751 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Chokeberry fiber placebo capsules
Study NCT05890989 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: EPICARDIAL ADIPOSIS TISSUE AND PHYSICAL PERFORMANCE MEASUREMENT
Description: EPICARDIAL ADIPOSIS TISSUE AND PHYSICAL PERFORMANCE MEASUREMENT OF THE PARTICIPANTS WAS MADE.
Study NCT05667363 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Digital Intervention
Description: Digital therapeutics are consist of a smartphone app and an intelligent medication recorder. The intelligent medication recorder can automatically record medication using data and reminds patients through the app. Patients can also record their symptom on the app for doctors to monitor.
Study NCT06035146 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mechanical energy monitoring
Description: Monitoring of the mechanical energy acting on the lung parenchyma during mechanical ventilation.
Study NCT06035146 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional mechanical ventilation
Description: The conventional procedure of mechanical ventilation controlled according to the physician's decision.
Study NCT05164484 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transpulmonary thermodilution
Description: Through the analysis of the thermodilution curve recorded at the tip of an arterial catheter after the injection of a cold bolus in the venous circulation, transpulmonary thermodilution intermittently measures cardiac output.
Study NCT05070637 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No-touch laparoscopic radical nephrectomy
Description: We aim to determine if a laparoscopic no-touch nephrectomy with an early renal pedicle ligation can decrease CTC release during surgery.
Study NCT05070637 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional laparoscopic radical nephrectomy
Description: Conventional laparoscopic radical nephrectomy, which implies manipulation of the kidney, opening of the Gerota's fascia, and manipulation of peri-nephric fat during dissection, and renal pedicle isolation.
Study NCT06436898 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined overground gait exoskeleton and FES applied to lower limb
Description: Gait rehabilitation for persons with stroke, with an overground exoskeleton combined with an electromyographically controlled FES applied to lower limb muscles during gait.
Study NCT06436898 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Overground gait exoskeleton
Description: Gait rehabilitation for persons with stroke, with an overground exoskeleton.
Study NCT05070637 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic total nephrectomy control arm
Description: Control arm in which a laparoscopic total nephrectomy will be performed in non-cancer patients.
Study NCT05269654 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: injectable poly-L-lactic acid
Description: Injectable biostimulant for volume loss
Study NCT05269654 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Normal Saline
Description: Sham Comparator
Study NCT05666063 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ambulatory Urodynamic Study
Description: Ambulatory urodynamic study is started after spontaneous diuresis of the patients. Ambulatory monitoring time is limited to each patient's own voiding cycle. The patient and a family member are instructed on the use of the event buttons on the patient module to flag incontinence, urgency, physical activity, and water drinking. With the use of catheters attached to microcomputers attached to their shoulders, patients are free to move around and engage in activities that may cause urinary incontinence. After voiding, the residual urine volume is first measured and then urethral and rectal catheters are placed. Monitoring is terminated when the patient feels that he cannot delay the urination sensation.Questionnaires that are routinely applied in our clinic will be applied in order to objectively evaluate the symptoms. Before urodynamics, urinary tract infection, whether symptomatic or not, must be routinely excluded with a complete urinalysis and urine culture.
Study NCT05115136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxepin
Description: 25mg dose of Doxepin will be administered one time, by mouth
Study NCT05115136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: 50 mg dose of Diphenhydramine will be administered one time, by mouth
Study NCT05599022 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Stimulation
Description: Transcutaneous Magnetic Stimulation
Study NCT05599022 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Stimulation
Description: Transcutaneous Magnetic Stimulation
Study NCT05904288 — intervention group
Intervention type: DEVICE
Intervention: Smartwatch Garmin Vivosmart [wearable sensor]
Description: Garmin Vivo Smart is a fitness tracker, which is aimed at collecting patient's motor activity and heart rate data from embedded Inertial Movement Unit (IMU) and Photoplethismograph (PPG) sensors.
Study NCT05904288 — intervention group
Intervention type: DEVICE
Intervention: Soturi™ [digital mobile app]
Description: Soturi software is a proprietary mobile application, for people with Parkinson's Disease (PD) designed to record symptoms, by means of self-report diary, set reminders for medication intake. Soturi™ Physical Exercise Program and Speech Exercise Program.
Study NCT05904288 — intervention group
Intervention type: OTHER
Intervention: Clinical Assessment
Description: Outpatient repeated-measures clinical evaluations, which include assessment of motor symptoms through MDS-UPDRS and ecological motor tasks, to observe changes with respect to medication intake, and changes over a 6 month period time.
Study NCT04956328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid Tablets
Description: Obeticholic Acid：Once a day (QD) by mouth (PO).
Study NCT04956328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UDCA
Description: UDCA：continue prestudy dose
Study NCT04956328 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UDCA
Description: UDCA：continue prestudy dose
Study NCT04956328 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06439355 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fasting blood test
Description: metabolic assays determination of food intake hormones oxidative stress and neurodegeneration marker assays
Study NCT06439355 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fasting blood test
Description: metabolic assays determination of food intake hormones oxidative stress and neurodegeneration marker assays
Study NCT06439355 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Subject interview
Description: socio-demographic data, medical and family history, treatment taken
Study NCT06439355 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subject interview
Description: socio-demographic data, medical and family history, treatment taken
Study NCT06439355 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor assessment
Description: MDS-UPDRS scale PART III